ICARE Social Media Post October 2019

Advances in Early Stage Breast Cancer Treatment for BRCA Carriers


New benefits from a PARP inhibitor, talazoparib, among BRCA carriers with early stage breast cancer. The current FDA approvals for the use of PARP inhibitors is limited to women with metastatic (stage IV) breast cancer. These drugs are being tested in early stage breast cancer to shrink down the tumor (called neoadjuvant treatment) before surgery to remove it.

Specifically, 6 months of neoadjuvant talazoparib monotherapy (treatment with only talazoparib) resulted in significantly improved rates of complete response in patients with operable (stage I-III) breast cancer.

Look for other treatment advances in BRCA carriers in our newsletter at https://inheritedcancer.net/newsletters/.

Permanent link to this article: https://inheritedcancer.net/post101519/